Gene: FGF3

2248
HBGF-3|INT2
fibroblast growth factor 3
protein-coding
11q13.3
Ensembl:ENSG00000186895 MIM:164950 Vega:OTTHUMG00000167888 UniprotKB:P11487
NG_009016.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.108e-1 (AD)  5.709e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PRAMEF70.822
PRAMEF60.796
OR51A20.768
ZP20.686
SLC22A310.685
GSTA50.684
OR10A30.656
C15orf530.656
OR2J30.613
RHBG0.609

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HHATL-0.26
CRB2-0.254
TTYH2-0.249
SFTPC-0.243
HPN-0.242
KIAA1755-0.241
FGFR2-0.239
GPRC5B-0.237
SLC39A12-0.236
LIFR-0.233

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA"25510870
C5495433-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid analog results in increased expression of FGF3 mRNA25716159
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FGF3 mRNA16483693
D004958Estradiol[Estradiol binds to ESR2 protein] which results in increased expression of FGF3 mRNA20404318
C006780bisphenol Abisphenol A results in decreased expression of FGF3 mRNA25181051
D004008DiclofenacDiclofenac results in increased expression of FGF3 mRNA26934552
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of FGF3 mRNA23550701
D006493HeparinHeparin affects the activity of FGF3 protein7592624
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of FGF3 mRNA26752646
D008727MethotrexateMethotrexate affects the expression of FGF3 mRNA18502557
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA"25510870
D011192Potassium DichromatePotassium Dichromate results in decreased expression of FGF3 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of FGF3 mRNA24780913
C017947sodium arsenitesodium arsenite affects the methylation of FGF3 gene28589171
C105686SU 5402SU 5402 results in decreased expression of FGF3 mRNA15355794
C105686SU 5402SU 5402 results in decreased expression of FGF3 mRNA12421715
D014284TriiodothyronineTriiodothyronine results in increased expression of FGF3 mRNA17403546
C003377taxifolintaxifolin results in decreased expression of FGF3 mRNA17541156
D014118Toxins, Biological"Toxins, Biological affects the expression of FGF3 mRNA"19682533
D014212TretinoinTretinoin affects the expression of FGF3 mRNA8800419
D014212TretinoinTretinoin affects the localization of FGF3 protein8800419
D014635Valproic AcidValproic Acid results in increased methylation of FGF3 gene29154799
D014635Valproic AcidValproic Acid affects the expression of FGF3 mRNA17963808

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005104fibroblast growth factor receptor binding-IEA-  
GO:0005515protein binding-IPI16263090  
GO:0008083growth factor activity-IEA-  
GO:00163031-phosphatidylinositol-3-kinase activity-TAS-  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0007165signal transduction-TAS2470007  
GO:0007267cell-cell signaling-TAS2470007  
GO:0007275multicellular organism development-IEA-  
GO:0008284positive regulation of cell proliferation-IGI8663044  
GO:0008543fibroblast growth factor receptor signaling pathway-IGI8663044  
GO:0008543fibroblast growth factor receptor signaling pathway-TAS-  
GO:0009653anatomical structure morphogenesis-TAS2470007  
GO:0010469regulation of signaling receptor activity-IEA-  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0030154cell differentiation-IEA-  
GO:0036092phosphatidylinositol-3-phosphate biosynthetic process-IEA-  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0051781positive regulation of cell division-IEA-  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0055026negative regulation of cardiac muscle tissue development-IMP20702560  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005622intracellular-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04810Regulation of actin cytoskeleton
hsa05200Pathways in cancer
hsa05218Melanoma
Reactome ID Reactome Term Evidence
R-HSA-109704PI3K CascadeTAS
R-HSA-112399IRS-mediated signallingTAS
R-HSA-1226099Signaling by FGFR in diseaseTAS
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-1643685DiseaseTAS
R-HSA-1839126FGFR2 mutant receptor activationTAS
R-HSA-190236Signaling by FGFRTAS
R-HSA-190241FGFR2 ligand binding and activationTAS
R-HSA-190242FGFR1 ligand binding and activationTAS
R-HSA-190370FGFR1b ligand binding and activationTAS
R-HSA-190377FGFR2b ligand binding and activationTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-2033519Activated point mutants of FGFR2TAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-2404192Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)TAS
R-HSA-2428924IGF1R signaling cascadeTAS
R-HSA-2428928IRS-related events triggered by IGF1RTAS
R-HSA-5654219Phospholipase C-mediated cascade: FGFR1TAS
R-HSA-5654221Phospholipase C-mediated cascade; FGFR2TAS
R-HSA-5654687Downstream signaling of activated FGFR1TAS
R-HSA-5654688SHC-mediated cascade:FGFR1TAS
R-HSA-5654689PI-3K cascade:FGFR1TAS
R-HSA-5654693FRS-mediated FGFR1 signalingTAS
R-HSA-5654695PI-3K cascade:FGFR2TAS
R-HSA-5654696Downstream signaling of activated FGFR2TAS
R-HSA-5654699SHC-mediated cascade:FGFR2TAS
R-HSA-5654700FRS-mediated FGFR2 signalingTAS
R-HSA-5654726Negative regulation of FGFR1 signalingTAS
R-HSA-5654727Negative regulation of FGFR2 signalingTAS
R-HSA-5654736Signaling by FGFR1TAS
R-HSA-5654738Signaling by FGFR2TAS
R-HSA-5655253Signaling by FGFR2 in diseaseTAS
R-HSA-5658623FGFRL1 modulation of FGFR1 signalingTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-74751Insulin receptor signalling cascadeTAS
R-HSA-74752Signaling by Insulin receptorTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26943773Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. (2016 Apr 5)Tan QOncotarget
22074045The FGF and FGFR Gene Family and Risk of Cleft Lip With or Without Cleft Palate. (2013 Jan)Wang HCleft Palate Craniofac J